139 related articles for article (PubMed ID: 12652627)
1. Successful immunosuppressive therapy for a child with Myelodysplastic syndrome.
Orimoto M; Maeda M; Cai LZ; Hayakawa J; Ueda T; Migita M; Asano T
Med Pediatr Oncol; 2003 May; 40(5):334-5. PubMed ID: 12652627
[No Abstract] [Full Text] [Related]
2. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
3. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
5. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
[TBL] [Abstract][Full Text] [Related]
6. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
[TBL] [Abstract][Full Text] [Related]
7. [Immunosuppressive therapy for low-risk MDS: markers for good response].
Chuhjo T
Rinsho Ketsueki; 2004 Apr; 45(4):274-80. PubMed ID: 15168442
[No Abstract] [Full Text] [Related]
8. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
Miyata A; Yasuda Y; Fujii S; Kikuchi T
Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
[TBL] [Abstract][Full Text] [Related]
9. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
Barrett J; Sloand E; Young N
Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061
[No Abstract] [Full Text] [Related]
10. A new translocation (4;12)(q21;q15) after combined immunosuppressive therapy in a case of hypoplastic myelodysplastic syndrome with translocation (12;15)(q23;q12).
Iwanaga M; Sadamori N; Amenomori T; Kawaguchi Y; Nakamura H; Matsuo T; Kuriyama K; Tomonaga M
Cancer Genet Cytogenet; 1998 Nov; 107(1):82-4. PubMed ID: 9809042
[No Abstract] [Full Text] [Related]
11. Transformation of childhood MDS-refractory anemia to acute lymphoblastic leukemia.
Goel R; Kumar R; Bakhshi S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):725-7. PubMed ID: 17921857
[TBL] [Abstract][Full Text] [Related]
12. [Myelodysplastic syndrome].
Urabe A
Gan To Kagaku Ryoho; 2005 Mar; 32(3):287-91. PubMed ID: 15791810
[TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Promising therapy for bone marrow failure from myelodysplastic syndromes.
Ann Intern Med; 2002 Aug; 137(3):I-27. PubMed ID: 12160383
[No Abstract] [Full Text] [Related]
14. Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A.
Goldenberg NA; Graham DK; Liang X; Hays T
Pediatr Blood Cancer; 2004 Dec; 43(7):718-22. PubMed ID: 15390303
[TBL] [Abstract][Full Text] [Related]
15. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
[TBL] [Abstract][Full Text] [Related]
16. Hypocellular myelodysplasia.
Sloand EM
Hematol Oncol Clin North Am; 2009 Apr; 23(2):347-60. PubMed ID: 19327588
[TBL] [Abstract][Full Text] [Related]
17. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression with ALG and CsA is first line treatment in children with SAA lacking an HLA identical sibling.
Békássy AN; Locasciulli A; Marsh JC; Socié G; Fuehrer M; Passweg J
Pediatr Blood Cancer; 2005 Sep; 45(3):359-60; author reply 361-2. PubMed ID: 15940724
[No Abstract] [Full Text] [Related]
19. Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolonged marrow failure after hemophagocytic syndrome.
Kaito K; Otsubo H; Takei Y; Usui N; Kobayashi M
Ann Hematol; 2003 Nov; 82(11):699-701. PubMed ID: 12961029
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia.
Yoshimi A; Baumann I; Führer M; Bergsträsser E; Göbel U; Sykora KW; Klingebiel T; Gross-Wieltsch U; van den Heuvel-Eibrink MM; Fischer A; Nöllke P; Niemeyer C
Haematologica; 2007 Mar; 92(3):397-400. PubMed ID: 17339190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
